OV-1004 Study Investigators are in Appendix 1.
Full-Length Original Research
Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years
Version of Record online: 1 MAR 2014
© 2014 The Authors. Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 55, Issue 4, pages 558–567, April 2014
How to Cite
Conry, J. A., Ng, Y.-T., Kernitsky, L., Mitchell, W. G., Veidemanis, R., Drummond, R., Isojarvi, J., Lee, D., Paolicchi, J. M. and The OV-1004 Study Investigators (2014), Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia, 55: 558–567. doi: 10.1111/epi.12561
- Issue online: 22 APR 2014
- Version of Record online: 1 MAR 2014
- Manuscript Accepted: 9 JAN 2014
|epi12561-sup-0001-TableS1.docx||Word document||31K||Table S1. Most frequently reported adverse events (≥10% of patients) during any exposure to clobazam (Safety Analysis Set).|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.